ARCA biopharma, Inc.

Symbol: ABIO

NASDAQ

3.372

USD

Market price today

  • -8.9230

    P/E Ratio

  • -0.1983

    PEG Ratio

  • 48.92M

    MRK Cap

  • 0.00%

    DIV Yield

ARCA biopharma, Inc. (ABIO) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.43%

Operating Profit Margin

-45.35%

Net Profit Margin

-31.14%

Return on Assets

-0.15%

Return on Equity

-0.15%

Return on Capital Employed

-0.23%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Thomas A. Keuer
Full-time employees:4
City:Westminster
Address:10170 Church Ranch Way
IPO:1997-08-08
CIK:0000907654

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

General Outlook

When we look at how much money they make before expenses, they keep 0.426% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -45.352%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -31.136%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.149% return, is a testament to ARCA biopharma, Inc.'s adeptness in optimizing resource deployment. ARCA biopharma, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.147%. Furthermore, the proficiency of ARCA biopharma, Inc. in capital utilization is underscored by a remarkable -0.227% return on capital employed.

Stock Prices

ARCA biopharma, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $3.5, while its low point bottomed out at $3.18. This variance in figures offers investors a lucid insight into the roller-coaster ride that is ARCA biopharma, Inc.'s stock market.

Liquidity Ratios

Analyzing ABIO liquidity ratios reveals its financial health of the firm. The current ratio of 2319.42% gauges short-term asset coverage for liabilities. The quick ratio (2270.90%) assesses immediate liquidity, while the cash ratio (2270.90%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio2319.42%
Quick Ratio2270.90%
Cash Ratio2270.90%

Profitability Ratios

ABIO profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -3410.23% underscores its earnings before tax deductions. The effective tax rate stands at -7.50%, revealing its tax efficiency. The net income per EBT, 91.30%, and the EBT per EBIT, 75.19%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -4535.23%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-3410.23%
Effective Tax Rate-7.50%
Net Income per EBT91.30%
EBT per EBIT75.19%
EBIT per Revenue-4535.23%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 23.19, it details the span from stock purchase to revenue. The 23 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding2271
Days of Payables Outstanding1912
Cash Conversion Cycle-1912
Payables Turnover0.19
Fixed Asset Turnover7.33

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.34, and free cash flow per share, -0.34, depict cash generation on a per-share basis. The cash per share value, 2.48, showcases liquidity position. Lastly, the operating cash flow sales ratio, -28.11, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.34
Free Cash Flow per Share-0.34
Cash per Share2.48
Operating Cash Flow Sales Ratio-28.11
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-103.06
Short Term Coverage Ratio-103.06

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.13%, highlights its total liabilities relative to assets. An interest coverage of -17.74 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.13%
Total Debt to Capitalization0.14%
Interest Coverage-17.74
Cash Flow to Debt Ratio-103.06
Company Equity Multiplier1.05

Per Share Data

Net income per share, -0.37, reflects the portion of profit attributed to each share. The book value per share, 2.57, represents the net asset value distributed per share, while the tangible book value per share, 2.57, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-0.37
Book Value Per Share2.57
Tangible Book Value Per Share2.57
Shareholders Equity Per Share2.57
Interest Debt Per Share0.02

Growth Ratios

EBIT growth, 31.14%, and operating income growth, 31.14%, offer insights into operational profitability progression. The net income growth, 42.32%, showcases bottom-line expansion, and the EPS growth, 42.19%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth2.63%
EBIT Growth31.14%
Operating Income Growth31.14%
Net Income Growth42.32%
EPS Growth42.19%
EPS Diluted Growth42.19%
Weighted Average Shares Growth0.04%
Weighted Average Shares Diluted Growth0.04%
Operating Cash Flow Growth54.05%
Free Cash Flow Growth54.06%
10-Year Operating CF Growth per Share99.55%
5-Year Operating CF Growth per Share96.75%
3-Year Operating CF Growth per Share78.79%
10-Year Net Income Growth per Share99.63%
5-Year Net Income Growth per Share96.41%
3-Year Net Income Growth per Share82.09%
10-Year Shareholders Equity Growth per Share-98.87%
5-Year Shareholders Equity Growth per Share-67.24%
3-Year Shareholders Equity Growth per Share-74.00%
Asset Growth-12.12%
Book Value per Share Growth-11.20%
R&D Expense Growth-78.67%
SGA Expenses Growth7.46%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -12,644,009.1, captures the company's total value, considering both debt and equity. Income quality, 0.94, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value-12,644,009.1
Income Quality0.94
Graham Number4.63
Return on Tangible Assets-14.10%
Graham Net Net2.54
Working Capital36,955,000
Tangible Asset Value37,020,000
Net Current Asset Value36,751,000
Average Payables348,000
Days Payables Outstanding1190
ROIC-19.15%
ROE-0.14%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.39, and the price to book ratio, 1.39, reflect the market's valuation relative to the company's book value. The price to sales ratio, 277.94, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -9.89, and price to operating cash flows, -9.88, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.39
Price to Book Ratio1.39
Price to Sales Ratio277.94
Price Cash Flow Ratio-9.88
Price Earnings to Growth Ratio-0.20
Enterprise Value Multiple-10.68
Price Fair Value1.39
Price to Operating Cash Flow Ratio-9.88
Price to Free Cash Flows Ratio-9.89
Price to Tangible Book Ratio0.66
Enterprise Value Over EBITDA1.73
EV to Operating Cash Flow2.52
Earnings Yield-21.79%
Free Cash Flow Yield-20.46%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of ARCA biopharma, Inc. (ABIO) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -8.923 in 2024.

What is the ticker symbol of ARCA biopharma, Inc. stock?

The ticker symbol of ARCA biopharma, Inc. stock is ABIO.

What is company IPO date?

IPO date of ARCA biopharma, Inc. is 1997-08-08.

What is company current share price?

Current share price is 3.372 USD.

What is stock market cap today?

The market cap of stock today is 48917941.000.

What is PEG ratio in 2024?

The current -0.198 is -0.198 in 2024.

What is the number of employees in 2024?

In 2024 the company has 4.